MedTrace Logo

Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder

NCT00606411 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to learn about the safety and effectiveness of oral (taken by mouth) topiramate in treating Sleep-Related Eating Disorder (SRED).

Conditions

  • Sleep-Related Eating Disorder

Interventions

DRUG

Topiramate or Placebo

25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • John W Winkelman, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2018-11-29
Completion
2018-11-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606411 on ClinicalTrials.gov